Antitumor effect of radioactive cisplatin (191Pt) on nude mice

被引:30
作者
Areberg, J [1 ]
Wennerberg, J
Johnsson, A
Norrgren, K
Mattsson, S
机构
[1] Malmo Univ Hosp, Dept Radiat Phys, S-20502 Malmo, Sweden
[2] Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Lund, Sweden
[3] Univ Hosp, Dept Oncol, Lund, Sweden
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2001年 / 49卷 / 03期
关键词
Pt-191-cisplatin; cisplatin; radiochemotherapy; mice;
D O I
10.1016/S0360-3016(00)01419-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the effect of Pt-191-cisplatin in vivo in terms of the antitumor effect and general toxicity on tumor-bearing nude mice. Methods and Materials: Tumor-bearing (human squamous cell carcinoma, AB) nude mice were divided into four groups and given, i.p,, physiological saline (controls), cisplatin, Pt-191-cisplatin (80 MBq/mg), or Pt-191-cisplatin (160 MBq/mg), respectively, Mortality and weight were used as parameters for monitoring general toxic effect, while specific growth delay (SGD) and the area under the logarithm of the relative tumor size curve (AUC-log[RTS]) were used to evaluate the antitumor effect of the treatments. Results: Both SGD and AUC-log(RTS) values showed that Pt-191-cisplatin was significantly (P < 0.05) more effective in retarding tumor growth than nonradioactive cisplatin, No differences in mortality between the different groups could be observed and no significant differences in weight change between the mice treated with cisplatin or Pt-191-cisplatin could be seen. Conclusion: Pt-191-cisplatin is a more effective drug than nonradioactive cisplatin in retarding tumor growth on nude mice without adding systemic toxic effects. We believe that radioactive cisplatin may prove to be an alternative to conventional cisplatin; however, the possible toxic effects on organs at risk have to be thoroughly investigated. (C) 2001 Elsevier Science Inc.
引用
收藏
页码:827 / 832
页数:6
相关论文
共 21 条
[1]  
Areberg J, 1999, ACTA ONCOL, V38, P221
[2]   In vitro toxicity of 191Pt-labeled cisplatin to a human cervical carcinoma cell line (ME-180) [J].
Areberg, J ;
Johnsson, A ;
Wennerberg, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (05) :1275-1280
[3]   Absorbed doses to patients from 191Pt-;193mPt- and 195mPt-cisplatin [J].
Areberg, J ;
Norrgren, K ;
Mattsson, S .
APPLIED RADIATION AND ISOTOPES, 1999, 51 (05) :581-586
[4]  
BEGG AC, 1980, BRIT J CANCER, V41, P93
[5]  
Gorodetsky R, 1998, INT J CANCER, V75, P635, DOI 10.1002/(SICI)1097-0215(19980209)75:4<635::AID-IJC23>3.0.CO
[6]  
2-6
[7]  
Ho S, 1998, CANCER-AM CANCER SOC, V83, P1894, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1894::AID-CNCR4>3.3.CO
[8]  
2-F
[9]  
HOESCHELE JD, 1982, RADIOCHIM ACTA, V31, P27
[10]  
Howell RW, 1986, P 4 INT RAD DOS S